{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:06:04Z","timestamp":1793502364265,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s13555-025-01454-7","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T09:15:57Z","timestamp":1752138957000},"page":"2495-2520","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Translational Pharmacokinetics of Icotrokinra, a Targeted Oral Peptide that Selectively Blocks Interleukin-23 Receptor and Inhibits Signaling"],"prefix":"10.1007","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct04621630","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Beverly","family":"Knight","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brinda","family":"Tammara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishit B.","family":"Modi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Dallas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saro","family":"Mardirosian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Laenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Leclercq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"DiLoreto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieve","family":"Adriaenssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren","family":"Moss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Polidori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siladitya Ray","family":"Chaudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seonghee","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Sensenhauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Ndifor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharth","family":"Sukumaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"Baguet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shefali","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Geist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Fourie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Patch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengzao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie A.","family":"Barros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Somani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Monshouwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"key":"1454_CR1","doi-asserted-by":"publisher","first-page":"1331217","DOI":"10.3389\/fimmu.2024.1331217","volume":"15","author":"JG Krueger","year":"2024","unstructured":"Krueger JG, Eyerich K, Kuchroo VK, et\u00a0al. IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy. Front Immunol. 2024;15:1331217.","journal-title":"Front Immunol"},{"key":"1454_CR2","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s40257-020-00578-0","volume":"22","author":"K Yang","year":"2021","unstructured":"Yang K, Oak ASW, Elewski BE. Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review. Am J Clin Dermatol. 2021;22:173\u201392.","journal-title":"Am J Clin Dermatol"},{"key":"1454_CR3","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3390\/jcm13010224","volume":"13","author":"J Fanizza","year":"2023","unstructured":"Fanizza J, D\u2019Amico F, Lusetti F, et\u00a0al. The role of IL-23 inhibitors in Crohn\u2019s disease. J Clin Med. 2023;13:224.","journal-title":"J Clin Med"},{"key":"1454_CR4","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3390\/pharmaceutics16010111","volume":"16","author":"A Drakos","year":"2024","unstructured":"Drakos A, Torres T, Vender R. Emerging oral therapies for the treatment of psoriasis: a review of pipeline agents. Pharmaceutics. 2024;16:111.","journal-title":"Pharmaceutics"},{"key":"1454_CR5","doi-asserted-by":"publisher","first-page":"141","DOI":"10.36469\/9817","volume":"4","author":"SR Feldman","year":"2017","unstructured":"Feldman SR, Holmen Moeller A, Erntoft Idemyr ST, Gonzalez JM. Relative importance of mode of administration in treatment preferences among plaque psoriasis patients in the United States. J Health Econ Outcomes Res. 2017;4:141\u201357.","journal-title":"J Health Econ Outcomes Res"},{"key":"1454_CR6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/jan.13818","volume":"75","author":"J McLenon","year":"2019","unstructured":"McLenon J, Rogers MAM. The fear of needles: a systematic review and meta-analysis. J Adv Nurs. 2019;75:30\u201342.","journal-title":"J Adv Nurs"},{"key":"1454_CR7","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","volume":"156","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Puig L, Joshi A, et\u00a0al. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol. 2020;156:258\u201369.","journal-title":"JAMA Dermatol"},{"key":"1454_CR8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","volume":"88","author":"AW Armstrong","year":"2023","unstructured":"Armstrong AW, Gooderham M, Warren RB, et\u00a0al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2023;88:29\u201339.","journal-title":"J Am Acad Dermatol"},{"key":"1454_CR9","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","volume":"88","author":"B Strober","year":"2023","unstructured":"Strober B, Thaci D, Sofen H, et\u00a0al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol. 2023;88:40\u201351.","journal-title":"J Am Acad Dermatol"},{"key":"1454_CR10","doi-asserted-by":"publisher","first-page":"4167","DOI":"10.1021\/jacs.8b13178","volume":"141","author":"AA Vinogradov","year":"2019","unstructured":"Vinogradov AA, Yin Y, Suga H. Macrocyclic peptides as drug candidates: recent progress and remaining challenges. J Am Chem Soc. 2019;141:4167\u201381.","journal-title":"J Am Chem Soc"},{"key":"1454_CR11","doi-asserted-by":"publisher","first-page":"8094","DOI":"10.1021\/acs.chemrev.6b00838","volume":"117","author":"DS Nielsen","year":"2017","unstructured":"Nielsen DS, Shepherd NE, Xu W, et\u00a0al. Orally absorbed cyclic peptides. Chem Rev. 2017;117:8094\u2013128.","journal-title":"Chem Rev"},{"key":"1454_CR12","doi-asserted-by":"publisher","first-page":"17515","DOI":"10.1038\/s41598-024-67371-5","volume":"14","author":"AM Fourie","year":"2024","unstructured":"Fourie AM, Cheng X, Chang L, et\u00a0al. JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humans. Sci Rep. 2024;14:17515.","journal-title":"Sci Rep"},{"key":"1454_CR13","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1056\/NEJMoa2308713","volume":"390","author":"R Bissonnette","year":"2024","unstructured":"Bissonnette R, Pinter A, Ferris LK, et\u00a0al. An oral interleukin-23-receptor antagonist peptide for plaque psoriasis. N Engl J Med. 2024;390:510\u201321.","journal-title":"N Engl J Med"},{"key":"1454_CR14","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.jaad.2024.10.076","volume":"92","author":"LK Ferris","year":"2024","unstructured":"Ferris LK, Bagel J, Huang YH, et\u00a0al. FRONTIER-2: a phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2024;92:495\u2013502.","journal-title":"J Am Acad Dermatol"},{"key":"1454_CR15","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1097\/00006454-198601001-00005","volume":"5","author":"KM Van de Graaff","year":"1986","unstructured":"Van de Graaff KM. Anatomy and physiology of the gastrointestinal tract. Pediatr Infect Dis. 1986;5:S11\u20136.","journal-title":"Pediatr Infect Dis"},{"key":"1454_CR16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v20.i23.30","volume":"20","author":"RI Mahato","year":"2003","unstructured":"Mahato RI, Narang AS, Thoma L, Miller DD. Emerging trends in oral delivery of peptide and protein drugs. Crit Rev Ther Drug Carrier Syst. 2003;20:153\u2013214.","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"1454_CR17","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.addr.2016.04.029","volume":"101","author":"CA Lipinski","year":"2016","unstructured":"Lipinski CA. Rule of five in 2015 and beyond: target and ligand structural limitations, ligand chemistry structure and drug discovery project decisions. Adv Drug Deliv Rev. 2016;101:34\u201341.","journal-title":"Adv Drug Deliv Rev"},{"key":"1454_CR18","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1002\/cpt.2847","volume":"113","author":"C Sall","year":"2023","unstructured":"Sall C, Argikar U, Fonseca K, et\u00a0al. Industry perspective on therapeutic peptide drug-drug interaction assessments during drug development: a European Federation of Pharmaceutical Industries and Associations white paper. Clin Pharmacol Ther. 2023;113:1199\u2013216.","journal-title":"Clin Pharmacol Ther"},{"key":"1454_CR19","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41573-019-0053-0","volume":"19","author":"DJ Drucker","year":"2020","unstructured":"Drucker DJ. Advances in oral peptide therapeutics. Nat Rev Drug Discov. 2020;19:277\u201389.","journal-title":"Nat Rev Drug Discov"},{"key":"1454_CR20","doi-asserted-by":"publisher","first-page":"297","DOI":"10.4161\/mabs.23684","volume":"5","author":"DK Shah","year":"2013","unstructured":"Shah DK, Betts AM. Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human. MAbs. 2013;5:297\u2013305.","journal-title":"MAbs"},{"key":"1454_CR21","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/exd.12863","volume":"25","author":"C Dragatin","year":"2016","unstructured":"Dragatin C, Polus F, Bodenlenz M, et\u00a0al. Secukinumab distributes into dermal interstitial fluid of psoriasis patients as demonstrated by open flow microperfusion. Exp Dermatol. 2016;25:157\u20139.","journal-title":"Exp Dermatol"},{"key":"1454_CR22","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1208\/s12248-014-9687-3","volume":"17","author":"L Di","year":"2015","unstructured":"Di L. Strategic approaches to optimizing peptide ADME properties. AAPS J. 2015;17:134\u201343.","journal-title":"AAPS J"},{"key":"1454_CR23","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s40262-013-0079-0","volume":"52","author":"L Diao","year":"2013","unstructured":"Diao L, Meibohm B. Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides. Clin Pharmacokinet. 2013;52:855\u201368.","journal-title":"Clin Pharmacokinet"},{"key":"1454_CR24","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","volume":"371","author":"KA Papp","year":"2008","unstructured":"Papp KA, Langley RG, Lebwohl M, et\u00a0al. Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371:1675\u201384.","journal-title":"Lancet"},{"key":"1454_CR25","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"K Reich","year":"2017","unstructured":"Reich K, Armstrong AW, Foley P, et\u00a0al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76:418\u201331.","journal-title":"J Am Acad Dermatol"},{"key":"1454_CR26","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","volume":"394","author":"K Reich","year":"2019","unstructured":"Reich K, Gooderham M, Thaci D, et\u00a0al. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet. 2019;394:576\u201386.","journal-title":"Lancet"},{"key":"1454_CR27","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","volume":"390","author":"K Reich","year":"2017","unstructured":"Reich K, Papp KA, Blauvelt A, et\u00a0al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017;390:276\u201388.","journal-title":"Lancet"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01454-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01454-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01454-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T01:29:34Z","timestamp":1757208574000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01454-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1454"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01454-7","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,8]]},"assertion":[{"value":"11 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Beverly Knight, Brinda Tammara, Shannon Dallas, Saro Mardirosian, Jianyao Wang, Aline Laenen, Laurent Leclercq, Karen DiLoreto, Lieve Adriaenssen, Darren Moss, David Polidori, Siladitya Ray Chaudhuri, Seonghee Park, Carlo Sensenhauser, Anthony Ndifor, Siddharth Sukumaran, Tristan Baguet, Yifan Shi, Shefali Patel, Brian Geist, Stephanie A Barros, Mario Monshouwer: Employee: Johnson & Johnson; Shareholder: may own stock\/stock options in Johnson & Johnson. Nishit B Modi: Employee: Protagonist Therapeutics, Inc. Anne Fourie, Raymond Patch: Former employee: Johnson & Johnson; Shareholder: may own stock\/stock options in Johnson & Johnson. Chengzao Sun, Sandeep Somani: Employee: Pinnacle Medicines; Former employee: Johnson & Johnson; Shareholder: may own stock\/stock options in Johnson & Johnson. Beverly Knight, Nishit B Modi, David Polidori and Anne Fourie are listed as inventors on United States patent application published as US20240254180, related to this work. Chengzao Sun, Sandeep Somani and Raymond Patch are listed as inventors on Patent Cooperation Treaty (PCT) international patent application published as WO2021\/146441, related to this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Rat study protocols and procedures were conducted under the United Kingdom Home Office project license number PP9376768 that controls scientific procedures on animals in the United Kingdom under the Animals (Scientific Procedures) Act 1986. The regulations conform to the European Convention for the Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes (Strasbourg, Council of Europe) and achieve the standard of care required by the United States Department of Health and Human Services\u2019 Guide for the Care and Use of Laboratory Animals. Monkey study protocols and procedures were reviewed and approved by the Charles River (Nevada) Institutional Animal Care and Use Committee and were conducted in compliance with applicable sections of the Final Rules of the Animal Welfare Act regulations (Code of Federal Regulations, Title 9), the Public Health Service Policy on Humane Care and Use of Laboratory Animals from the Office of Laboratory Animal Welfare, the Guide for the Care and Use of Laboratory Animals from the National Research Council. The FIH study protocol was reviewed and approved by Alfred Hospital Ethics Committee (Project 613\/20 HREC\/69080\/Alfred-2020). The Human Research Ethics Committee (HREC) gave written approval for the Phase 1 FIH study, in accordance with local regulations. The HREC was appropriately constituted and operated in accordance with the Notes for Guidance on Good Clinical Practice (GCP, CPMP\/ICH\/15\/95), as adopted by the Australian Therapeutic Goods Administration (TGA, 2000) and the National Health and Medical Research Council (NHMRC) National Statement on Ethical Conduct in Human Research (2007, updated 2018). Each subject gave informed consent at the screening visit to participate in the study and publication. This study was conducted in accordance with the principles of the current Declaration of Helsinki (Ethical Principles for Medical Research Involving Human Subjects), the NHMRC National Statement on Ethical Conduct in Human Research (2007, updated 2018), and Notes for Guidance on GCP (CPMP\/ICH\/135\/95) established from the International Conference on Harmonization guidelines and adopted by the Australian TGA (2000). All study investigations were undertaken by scientifically and medically qualified persons. The relative bioavailability study protocol was reviewed and approved by FAGG (federal agency for medicines and health products in Belgium; reference number R&D\/1317536). The study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with GCPs and applicable regulatory requirements. Informed consent was gained prior to the commencement of any study procedures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}